AGEN1884, an Anti-CTLA-4 Human Monoclonal Antibody in Participants With Advanced or Refractory Cancer and Who Have Progressed With PD-1/PD-L1 Inhibitor as Their Most Recent Therapy

NCT02694822 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

89

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Cancers
Advanced Solid Cancers Refractory to PD-1 and PD-L1 Therapies

Interventions

DRUG: Zalifrelimab

Sponsor

Agenus Inc.